Molecular Targeted Therapy

• 3895 3895 Targeting RET fusions in sarcomas with vepafestinib, a 3rd generation RET inhibitor with superior blood-brain barrier penetration Ryan Cheng, Allan J. W. Lui, Tom Zhang, Christopher A. Febres-Aldana, Michael Trombetta, Qing Chang, Inna Khodos, Elisa de Stanchina, Igor Odintsov, Marc Ladanyi, Romel Somwar
• 3896 · PDF MERTK inhibitor MRX-2843 sensitizes AML to venetoclax and azacitidine in preclinical models Aashis Thapa, Chloe Hope, Edward B. Henderson, Austre Y. Schiaffino Bustamante, Gianna Branella, Alejandro De Janon, Sunil Raikar, Xiaodong Wang, Stephen V. Frye, H. Shelton Earp, Shuichi Takayama, Deborah DeRyckere, Douglas K. Graham
• 3898 · PDF Profiling tumor selectivity of state- and paralog-selective RAS inhibitors through a signaling inhibition index (SII) Beau Baars, Ana Orive-Ramos, Matthew Emmett, Bijaya Gaire, Mathieu Desaunay, Ziyue Kou, Guangyan Li, Christos Adamopoulos, Stuart A. Aaronson, Shaomeng Wang, William R. Sellers, Tiphaine Martin, Evripidis Gavathiotis, Poulikos I. Poulikakos
• 3900 · PDF Tegavivint, a first-in-class TBL1 inhibitor demonstrates potent activity in WNT-driven colorectal cancers Raffaella Soldi, Tithi Ghosh Halder, Jaeger Moore, Serina Ng, Jamie Cox, Taylor Bargenquast, Mahtab Youseffi, Julissa Simmons, Elena Ramirez, Aundrietta Duncan, Stephen Horrigan, Sunil Sharma
• 3901 · PDF BGB-58067, a brain-penetrative MTA-cooperative PRMT5 inhibitor, demonstrates promising anti-tumor activity and favorable selectivity in tumors with MTAP-deletion Amy Jiang, Jinyan Chen, Xiaoxin Liu, Hongyu Chen, Huijun Kang, Jie Li, Haiying Li, Bo Zhang, Chenge Zhao, Hao Zhu, Xin Zhou, Sanjia Xu, Yibin Xu, Xing Zhou, Shifan Ma, Ming Fang, Min Xu, Lan Hua, Chuanxiu Yang, Yue Wu, Beibei Jiang, Xi Wu, Fan Wang, Ye Liu, Zhitao Wan, Jing Li, Jiyuan Zhang, Zhiwei Wang, Zhirong Shen, Yu Shen, Lai Wang, Xiaomin Song
• 3902 · PDF WEE1 inhibition as a therapeutic strategy in triple-negative breast cancer: Evaluating single agent and combination activity of azenosertib in preclinical models Catherine Lee, Alexandra Levy, Mona Abed, Heekyung Chung, Olivier Harismendy, Doris Kim
• 3903 3903 SPEDOX-6: First-in-human Phase IB/IIA trial on soft tissue sarcomas C. J. Yu, leslie Wang, Kinsley Wang, Mengmeng Liu, Faqing Huang, Warren A. Chow, Xiaojiang Cui
• 3904 · PDF SPOP drives AR-V7-mediated ARPI resistance in prostate cancer Joanina K. Gicobi, Susanna M. Gregory, Nicole A. Becker, Elizabeth A. Bering, Jacob J. Orme
• 3905 · PDF A pan-TEAD inhibitor, SIGX2649, blocks Hippo-YAP/TAZ signaling pathway and suppresses solid tumor growth in preclinical studies Hualing Peng
• 3906 3906 Small-molecule inhibitors as salvage therapy for CBFB::MYH11-associated acute myeloid leukemia Thuy An Nguyen, A S M Waliullah, Joshua Pei, Misha Padigala, Malena Nong, Nazifa Azam, Hien La, Nicholas Nguyen, Katelyn Do, Ramzia Ismailzada, Anna Bookstaver, Barbara Dziegielewska, Ly P. Vu, Nam Chu, Francine Garrett-Bakelman, Hong Zhu, Jeffrey W. Craig, Bon Q. Trinh
• 3907 · PDF Molecular determinants of response in laparoscopically triaged advanced ovarian cancer Sara Corvigno, Nicholas W. Bateman, Amma Asare, Chunqiao Tian, Jun Yao, Sean Cronin, Jonathan Ogata, Tamara Abulez, Kelly A. Conrads, Brian L. Hood, Joseph Celestino, Nicole D. Fleming, Kathleen M. Darcy, Amir A. Jazaeri, Shannon N. Westin, Christopher Tarmey, Thomas P. Conrads, George L. Maxwell, Sanghoon Lee, Anil K. Sood
• 3908 3908 Liquid biopsy-informed precision oncology clinical trial to evaluate the utility of ctDNA genomic profiling for therapy optimization in patients with advanced or metastatic solid tumors Amna Jamali, Jaime Wehr, Jenna VanLiere Canzoniero, Maria Fatteh, Katerina Karaindrou, Michael Conroy, Ilias Ziakas, Mohamed Sherief, Timsy Wanchoo, Faith Too, Lily Scharpf, Ruth Moges, Dana Petry, Kala Visvanathan, Ellen Verner, Amy Greer, Kory Kreimeyer, Jonathan Spiker, Rachel Karchin, Christine L. Hann, Vincent K. Lam, Joseph Christopher Murray, Josephine Feliciano, Kristen Marrone, Julie R. Brahmer, Ming-Tseh Lin, Taxiarchis Botsis, Hao Wang, Mark Sausen, Christopher D. Gocke, Rena Xian, Jessica Tao, Valsamo (Elsa) K. Anagnostou
• 3909 · PDF SMARCA4 ablation mitigates distal-less homeobox 1 ( DLX1 )- driven oncogenicity in prostate cancer Ankita Bhattacharyya, Susanta Samajdar, Bushra Ateeq
• 3910 · PDF AR copy number amplification and AR/KLK3 expression patterns reveal mechanisms of AR signaling inhibitor (ARSI) resistance and highlight the need for AR-directed therapeutic innovation in metastatic castration resistance prostate cancer (mCRPC) Celine Robert-Tissot, Phuong A. Nguyen, Elisabeth A. Murphy, Yawei J. Yang, Evisa Gjini, Michaela Bowden
• 3911 · PDF Use of ALK inhibitors in patients with non-lung malignancies bearing ALK alteration prolongs treatment duration Vitor Abreu de Goes, Miguel Zugman, Koral Shah, Ali Moradi, Salvador Jaime-Casas, Yu Jun Li, Daniela V. Castro, Benjamin Mercier, Jadon Fann, JoAnn Hsu, George Zhang, Vicki Doctor, Amber Moran, Maurie Markman, Alexander Chehrazi-Raffle, Charles Nguyen, Sumanta Kumar Pal
• 3912 · PDF NQO1 as a target to overcome therapy resistance in multiple myeloma Seungbin Han, Christina Verbruggen, Lenka Besse, Shilpa Kurian, Silvia Nerreter, Umair Munawar, Marietta Truger, Elena Gerhard-Hartmann, Andrej Besse, Ann-Sophie Hainold, Cornelia Vogt, Emma Besant, Nina Rein, Max Köppel, Xiang Zhou, Claudia Haferlach, Andreas Rosenwald, Christoph Driessen, Ondrej Slaby, Hermann Einsele, Leo Rasche, Markus Sauer, Johannes Waldschmidt, K. Martin Kortüm
• 3913 · PDF Inavolisib demonstrates anti-tumorigenic effects in pre-clinical models of serous endometrial cancer Miller Singleton, Haomeng Zhang, Alexandra Diggs, Braxton Burnett, Kristen N. Taylor, Chunxiao Zhou, Victoria Lin Bae-Jump
• 3914 · PDF Inavolisib exhibits anti-proliferative effects in pre-clinical model of endometrioid endometrial cancer Alexandra Diggs, Haomeng Zhang, Miller Singleton, Braxton Burnett, Kristen N. Taylor, Chunxiao Zhou, Victoria Lin Bae-Jump
• 3915 · PDF From bench to bedside: A CNS penetrant and Omnipotent EGFR inhibitor, WSD0922-FU targeting primary mutations and the C797S acquired resistance mutation shapes the treatment landscape of EGFR mutant NSCLC Wei Zhong, Yue Liu, Carina Yu, Xiaolei Wang
• 3916 · PDF A potent CDK7 inhibitor TY-2699a has the potential for combination with chemotherapy or immunotherapy in solid tumors Shengli Dong*, Apeng Liang*, Zhengfei Guo, Zhiyong He, Meihua Li, Xinlong Yang, Chao Zhou, Yu Yu, Hongqiang Li, Jian Zhu, Chengshan Niu, Shaoqing Chen, Jun Li, Yusheng Wu
• 3918 · PDF FGFR2 might be a promising therapeutic target for some types of carcinomas: Analysis of 1312 tumors with FGFR2 abnormalities Hinano Nishikubo, DONGHENG MA, Tomoya Sano, Canfeng Fan, Daiki Imanishi, Takashi Sakuma, Yurie Yamamoto, Masakazu Yashiro
• 3919 · PDF The emerging role of claudin 18.2 as a potential driver in gastric cancer progression Lisa Negro, Elisabetta Puliga, Emanuela Boccuni, Simona Corso, Silvia Giordano
• 3920 · PDF PIK3CA and ARID1A co-altered tumors are sensitive to AKT inhibitor, capivasertib Rian Engeldinger, Shirsa Udgata, Jordan Noelle Stoecker, Xingqi Shen, Ruchi Shah, Alexa Schmitz, Katherine A. Johnson, Cheri Pasch, Dustin A. Deming
• 3921 · PDF Periostin on tumor stromal cells might be associated with the malignant progression of patients with gastric cancer Canfeng Fan, Hinano Nishikubo, DONGHENG MA, Tomoya Sano, Daiki Imanishi, Takashi Sakuma, Yurie Yamamoto, Masakazu Yashiro
• 3922 · PDF Polymeric delivery of TRAIL mRNA for inducing apoptosis in non-small cell lung cancer Gurkirat Singh Sandhu, Hasan Uludag
• 7789 7789 ACM-CpG, a polymersome-delivered TLR9 agonist, elicits rapid and broad immune activation in a phase I trial for advanced solid tumors Amit Jain, Aaron C. Tan, Andrea Budiman, Nan Jiang, Kim Peng Tan, Jackwee Lim, Loo Ser Yue, Jian Hang Lam, Yan Jun Lee, Teck Wan Chia, Katherine Schultheis, Madhavan Nallani, Daniel Sw Tan

在会议检索中浏览本分会场